Answering a question from
@Pharmdca post: why the recent run from $10-$35?
1. New proven biotech leadership; Rick Barry at HELM
2. Nearing P3 readout EOY
3. ~ 90% of patients matriculated to OLE with no safety issues
4. 38% shorts, low float
5. Institutions buying
Go
$SAVA